Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer.

Yi-Long WuRafal DziadziuszkoJin Seok AhnFabrice BarlesiMakoto NishioDae Ho LeeJong-Seok LeeWenzhao ZhongHidehito HorinouchiWeimin MaoMaximilian HochmairFilippo de MarinisM Rita MigliorinoIgor BondarenkoShun LuQun WangTania Ochi LohmannTingting XuAndres CardonaThorsten RufJohannes NoeBenjamin J Solomonnull null

Published in: The New England journal of medicine (2024)

-positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.).

Keyphrases

free survival
advanced non small cell lung cancer
small cell lung cancer
early stage
lymph node
locally advanced
squamous cell carcinoma
prognostic factors
tyrosine kinase
chemotherapy induced